Skip to Content


Active Substance: pramipexole dihydrochloride monohydrate
Common Name: pramipexole
ATC Code: N04BC05
Marketing Authorisation Holder: Dr. Karl Thomae GmbH
Active Substance: pramipexole dihydrochloride monohydrate
Status: Withdrawn
Authorisation Date: 1997-10-27
Therapeutic Area: Parkinson Disease
Pharmacotherapeutic Group: Anti-parkinson drugs

Therapeutic Indication

DAQUIRAN tablets are indicated for treatment of the signs and symptoms of advanced idiopathic Parkinson's disease in combination with levodopa, i.e. over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on off" fluctuations).

The marketing authorisation for Daquiran has been withdrawn at the request of the marketing authorisation holder. 

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.